Targeting CD47? UCLA joins bandwagon, with gel to stem tumors from resurfacing
Hitting the “don’t eat me” CD47 receptor target has galvanized an army of drug developers who want to make inroads in the burgeoning field of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
